Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Gainesville, Florida


Purpose:

The primary objective of this study is to compare the urinary excretion of 14C-labeled risedronate and alendronate over 28 days.


Criteria:

Inclusion Criteria: - have medical history documentation verifying postmenopausal status of at least 2 years (natural or surgical). If not documented, confirmation will be required using estradiol < 20 pg/mL and follicle stimulating hormone (FSH) > 40 IU/mL; - have osteopenia or osteoporosis (< 1.002 g/cm2 Lunar or < 0.882 g/cm2 Hologic) as determined by DXA of the lumbar spine (AP or PA view, L1-L4). This corresponds to a T-score of approximately < -1.5. Exclusion Criteria: - any clinically significant out-of-range laboratory values and vital signs, - a clinically significant cardiovascular, hepatic, renal, or parathyroid disease, in the opinion of the Investigator - a known hypersensitivity to bisphosphonates


NCT ID:

NCT00577850


Primary Contact:

Study Director
Amy Sun, MD, PhD
Procter and Gamble


Backup Contact:

N/A


Location Contact:

Gainesville, Florida
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.